Navigation Links
Vermillion Reports Third Quarter 2013 Results
Date:11/14/2013

AUSTIN, Texas, Nov. 14, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the third quarter ended September 30, 2013.

Q3 2013 Financial Results
Total revenue in the third quarter of 2013 was $330,000 compared to $319,000 in the same year-ago quarter. Third quarter 2013 revenue was comprised of $216,000 in OVA1® product sales and $114,000 in license revenue.

Third quarter of 2013 product revenue was derived from 4,328 OVA1 tests performed at the fixed $50 per test as reported by Quest Diagnostics. This represents a 5.6% increase in test volume compared to approximately 4,100 OVA1 tests performed in the year-ago quarter. Although covered lives have decreased to approximately 67.0 million due to the previously announced BlueCross BlueShield Technical Evaluation Center position, it did not affect test sale volumes for the quarter.

The OVA1 product revenue in both periods does not include the additional royalty component of revenue based on 33% of Quest Diagnostics gross margin. Vermillion recognizes this portion of revenue when it is reported by Quest Diagnostics in an annual 'true-up' after the end of the calendar year. The true-up is based on reimbursed and unreimbursed tests for which Quest Diagnostics considers the payment status as final.

Total operating expenses were $2.6 million in both the third quarter of 2013 and the same year-ago quarter. For the nine months ended September 30, 2013, total operating expenses were $7.9 million as compared to $9.0 million in the same year-ago period.

Net loss for the third quarter was $2.3 million or $(0.10) per share, as compared to a net loss of $2.0 million or $(0.13) per share in the same year-ago quarter. For the nine months ended September 30, 2013, net loss was $7.0 million or $(0.36) per share as compared to a net loss of $5.8 million or $(0.39
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
2. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
3. Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
4. Vermillion Appoints Dr. Eric Varma to its Board of Directors
5. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
6. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
7. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
8. Vermillion Reports Fourth Quarter and Full Year 2012 Results
9. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
10. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
11. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Office (USPTO) has issued a key patent covering ... vaccine targeting six tumor antigens that are commonly ... No. 8,871,211, which issued October 28, 2014, include ... dendritic cell composition comprising peptide epitopes of the ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... December 15, 2014 BerGenBio AS, ... aggressive drug resistant cancers, today announces that it has ... placing from new and existing investors. BerGenBio ... the development of its pipeline of innovative cancer therapeutics, ... lead drug candidate, BGB324, a first-in-class selective Axl kinase ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2
... DIEGO, March 10, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... today announced financial results for the three months and year ended ... 31, 2010 For the three months ended December ... $0.24 per share, as compared to a net loss of $15.0 ...
... 2011 Dendreon Corporation (Nasdaq: DNDN ) ... (FDA) approved the remainder of its New Jersey manufacturing ... of PROVENGE® (sipuleucel-T) to help meet the needs of ... (hormone refractory) prostate cancer.   Last April, ...
Cached Medicine Technology:Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 2Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 3Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 4Dendreon Expands Launch of PROVENGE 2Dendreon Expands Launch of PROVENGE 3Dendreon Expands Launch of PROVENGE 4Dendreon Expands Launch of PROVENGE 5
(Date:12/19/2014)... December 19, 2014 Slone ... diagnostic, personalized medicine, healthcare information technology, and laboratory ... position of Chief Operating Officer. The announcement comes ... marked by a strengthened presence in Boston and ... "Leslie lives and breathes the client experience," said ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Being in good ... researchers report. They looked at data from more than ... who underwent treadmill tests between 1991 and 2009. Those ... chance of having high blood pressure at the start of ... with high levels of fitness. Of the more than ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Unidesk ... Osteopathic Medicine (ACOM), which welcomed its inaugural class ... Infrastructure (VDI) to seamlessly support bring your own ... and teaching – experience. The solution, comprised of ... , Dell server and storage infrastructure ...
(Date:12/17/2014)... Miami, FL (PRWEB) December 17, 2014 ... has not been able to eradicate the head louse ... and hassle for parents. Each year between six and ... Lice Troopers, the Miami-based lice removal treatment company comes ... safe, non-toxic and environmentally friendly. With its track record ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... 28 Dr. Eaton E.,Lattman, currently Dean of Research ... and Sciences at Johns Hopkins University (JHU), has,been appointed ... Research Institute. Lattman will assume the,position on July 1, ... has degrees from Harvard and JHU and at JHU ...
... medications longer, study finds , , FRIDAY, March 28 (HealthDay ... than the older drug haloperidol in treating a first ... it appears that more patients prefer the newer drugs ... haloperidol, the study authors said. , "When we compared ...
... Raleigh County League of,Democratic Women will conduct a mock ... Clinton and Barack Obama., "We,re not expecting the ... each one will be represented by two local,volunteers supporting ... be held at 6 p.m. Tuesday at the Raleigh ...
... using whole body 16 multi-detector CT (MDCT); theres no need ... recent study conducted by researchers at the University of Maryland ... in Baltimore, MD. The study showed that whole body MDCT ... In the past, blunt trauma patients would undergo whole-body MDCT ...
... from Boston University School of Medicine (BUSM) and ... found that decreased sexual satisfaction in postmenopausal women, ... study appears in the April 2008 issue of ... dysfunction is a common condition and has been ...
... to try technology like sensors,to detect falls and ... perception, and technical issues remain challenges, WASHINGTON, ... so they can age safely in their home. ... the challenges of caregiving.,Concerns such as cost to ...
Cached Medicine News:Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Whole body MDCT just as 'good' as neck MDCT angiography in diagnosing head and neck injuries 2Health News:Decreased sexual satisfaction is not associated with cardiovascular disease in postmenopausal women 2Health News:Older People Want to Use Technology to Help Them Remain at Home 2Health News:Older People Want to Use Technology to Help Them Remain at Home 3Health News:Older People Want to Use Technology to Help Them Remain at Home 4
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
... Melt), A low temperature agarose for ... , Optimal for in-gel restriction digestion/ligation and ... very manageable clear gel that provides excellent ... approximately 65°C and remains fluid at 37°C ...
... UltraClean Agarose, Molecular Biology ... electrophoretic separation of nucleic acids. ... isolate DNA fragments from 0.2 ... of UltraClean Agarose is tested ...
Medicine Products: